Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Disease 1

Interventions

Tomography, X-Ray Computed 2Hematologic Tests 2Blood Specimen Collection 2tivozanib 1pembrolizumab 1aflibercept 1Videotape Recording 1Urination 1Thoracoscopy 1Thoracic Surgical Procedures 1Sulfonylurea Compounds 1Sodium-Glucose Transporter 2 Inhibitors 1Referral and Consultation 1Octreotide 1Magnetic Resonance Spectroscopy 1Lymph Node Excision 1Ipilimumab 1Interviews as Topic 1Interleukin-15 1In Situ Hybridization 1Immunohistochemistry 1Exercise 1Erlotinib Hydrochloride 1Equipment and Supplies 1Educational Status 1Dipeptidyl-Peptidase IV Inhibitors 1Diagnostic Tests, Routine 1Diagnosis 1Clinical Laboratory Techniques 1Bupivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × tivozanib × Thoracic × Clear all
NCT01728181 2013-07-25

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

University of Utah

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡